Intelligent Bio (NASDAQ: $INBS ) Announces New Zealand

New Post Public Reply Private Reply Replies (0) Message Board
louied91
238
Intelligent Bio (NASDAQ: $INBS ) Announces New Zealand Expansion: Medical Stocks Growing Momentum” $INBS, $XTRX, $CNXA, $DNA

https://www.barchart.com/story/news/21382384/...x-cnxa-dna

As markets are volatile due to inflation fears, “Biotech Medical” companies stay the course, here is a look into four stocks that have buzzed recently.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company involved in providing fast, intelligent, and non-invasive testing solutions. Intelligent Bio Solutions Inc. asserts that the Intelligent Fingerprinting Drug Screening System that it developed would change the face of portable testing through fingerprint sweat analysis. On October 24, the company announced that it had expanded into the New Zealand market. It was another major milestone for its Intelligent Fingerprinting Drug Screening System. The harm caused by drugs amounts to an eye-popping $1.9 billion a year.

The President and Chief Executive Officer of the company, Harry Simeonidis, spoke about the latest move as well. He noted that everyone at Copay was delighted at the expansion into the New Zealand market. It was also the completion of another key growth milestone for the company, he noted.

Earlier this month, the company announced that its Intelligent Fingerprinting Drug Screening System had been adopted by VKVP Haulage, the container logistics specialist. The company also revealed that it had been successful in completing 25000 intelligent fingerprinting tests with Auctus Management Group, its existing customer.

It was also revealed that the system from Intelligent Bio Solutions would be used to complement the alcohol testing program that VKVP Haulage already had in place. That would help VKVP Haulage inculcate the best practices of the industry in its fleet of 80 HGV trucks. Auctus Management Group deployed the company’s system to complete the 25000 tests as part of the work induction procedure for a significant rail construction project.

Also, the company announced that it had successfully completed the underwritten public offer of units. Intelligent Bio Solutions revealed that it raised $4.378 million in gross proceeds from the offering and major reason why the stock has experienced a significant decline in the last several weeks.

Xortx Therapeutics (NASDAQ: XRTX | TSXV: XRTX) On October 20, the company’s stock gained momentum and ended up with notable gains amidst a sharp rise in trading volume. Although there was no news about Xortx Therapeutics, the stock gained considerable traction, and at one point it had clocked gains of 110%.

That being said, on October 25, the company is going to host a special shareholder meeting. At that meeting, the company would have a vote on a share consolidation plan. Xortx is looking to boost its share price through a reverse stock split. The necessity is understandable since the stock could be delisted from NASDAQ since the shares have been trading lower than the minimum bid price requirement of $1. Additionally, it also emerged that Institutional Shareholder Services (ISS) recommended the company’s shareholders vote in favor of the move.

Connexa Sports Technologies Inc. (NASDAQ: CNXA) On October 19, the company was in focus after it announced its operating results for the quarter that ended on July 31, 2023. Connexa Sports Technologies Inc. reported revenues of $3.1 million for the quarter, which reflected a drop from the revenues of $3.6 million in the corresponding quarter last year.

The company reported operating losses of $1.9 million, which worked out to a 40% decrease from the loss of $3.1 million in the same period last year. Connexa Sports also launched its Slinger Bag Pickleball Launcher product in the United States, the fastest-growing racquet sports market and home to 5 million players. The company also announced that it met four out of the five NASDAQ compliance requirements. Connexa Sports noted that the company expected that fifth requirement to be met by the deadline of January 22, 2024.

Gingko Bioworks (NYSE: DNA): The company is known for working on the development of a major platform related to cell programming and biosecurity. On October 19, Gingko Bioworks made a joint announcement with the Government of Serbia. It emerged that the company and the Serbian government had signed a Memorandum of Understanding with the aim of working together to promote the bioeconomy of Serbia.

As per the plans of the partnership, the company and the Serbian Ministry of Science, Technology Development, and Innovation would collaborate on the development of a startup accelerator. The accelerator would deploy the horizontal platform Gingko and the company’s considerable expertise to help Serbian companies build through biology. Companies in Serbia would then be able to use the comprehensive research and development services if they were included in the accelerator. The services from Gingko would help the startups progress with their projects at a faster pace, which may have otherwise required considerable financial and infrastructural investment.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 79

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 189

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 85

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 129

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 389

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 0

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading

Top 5 Most Recently Viewed Articles

Vor Bio's Exploration of Strategic Alternatives for Growth

Updated Category News Views 213

Vor Bio Announces Exploration of Strategic Alternatives Today, Vor Bio, a clinical-stage cell and genome engineering company, has taken significant steps to enhance shareholder value. The decision comes at a time when the clinical data from its major programs suggests that reevaluating its approach could be beneficial in the face of challenging fundraising conditions....

Continue Reading
Kraig Biocraft Achieves Record Production in Spider Silk Fibers

Updated Category News Views 56

Kraig Biocraft Laboratories' Milestone in Spider Silk Production Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a pioneering firm renowned for its innovative developments in spider silk-based fibers, is thrilled to share the successful conclusion of its fourth production cycle for the year. This cycle represents a remarkable achievement, showcasing record-breaking...

Continue Reading
Gen X Faces Retirement Challenges: Understanding the Crisis

Updated Category News Views 282

Gen X’s Coming Retirement Crunch Gen X—often called the “sandwich generation”—is being pulled in two directions at once and edging toward a retirement problem many don’t fully see. With money, time, and attention split between family and work, long-term savings can drift to the back burner. The worry isn’t abstract; it’s about whether the money will be...

Continue Reading
Luxurious Villa Spectre: A $55 Million Icon of Elegance

Updated Category News Views 342

Villa Spectre: A $55 Million Marvel of Luxury Living Villa Spectre has recently captured the spotlight as the highest-priced sale in the area, setting a remarkable benchmark in luxury real estate. This impressive estate was sold for $55,000,000, showcasing the allure and opulence that the elite have come to expect from high-end properties. A Visionary Creation Designed by...

Continue Reading
Mosaic Minerals Shifts Focus to Gold with Amanda Acquisition

Updated Category News Views 333

Mosaic Minerals Re-prioritizes Focus on Gold Exploration Mosaic Minerals Corporation (CSE: MOC) is making a strategic pivot in its exploration efforts. The company has announced the cessation of its lithium exploration initiatives, particularly those in Jamésie, Quebec. Instead, Mosaic is setting its sights on more promising ventures in gold and nickel, specifically...

Continue Reading